Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1849-1856

  Tap, William D ^a   Demetri, George ^c   Barnette, Phillip ^d   Desai, Jayesh ^e   Kavan, Petr ^f   Tozer, Richard ^g   Benedetto, Pasquale W ^h   Friberg, Gregory ^b   Deng, Hongjie ^b   McCaffery, Ian ^b   Leitch, Ian ^b   Badola, Sunita ^b   Chang, Sung ^b   Zhu, Min ^b   Tolcher, Anthony ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMGEN INC   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f MCGILL UNIVERSITY   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ START   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANITUMAB; SOMATOMEDIN C;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RNA SEQUENCE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 84863908472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2359     Document Type: Article

References (21)

1. El Weshi A, Memon M, Raja M, et al: VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. Am J Clin Oncol 27:529-534, 2004 (Pubitemid 39371953)
2. Barker LM, Pendergrass TW, Sanders JE, et al: Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23:4354-4362, 2005 (Pubitemid 46207009)
3. Lal DR, Su WT, Wolden SL, et al: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 40:251-255, 2005 (Pubitemid 40143567)
4. Prieur A, Tirode F, Cohen P, et al: EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275-7283, 2004 (Pubitemid 39014452)
5. Calzone FJ, Cajulis E, Chung Y-A, et al: Domain-specific mechanisms of receptor inhibition by AMG 479, a fully-human IGF1R targeted antibody. Proceedings of the 99th Annual Meeting of the American Association for Cancer Res, Philadelphia, PA, April 11-15, 2008 (abstr 3994)
6. Beltran PJ, Mitchell P, Chung YA, et al: AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8:1095-1105, 2009
7. Beltran PJ, Chung YA, Moody G, et al: Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 337:644-654, 2011
8. Tolcher AW, Sarantopoulos J, Patnaik A, et al: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807, 2009
9. Lee JJ, Liu DD: A predictive probability design for phase II cancer clinical trials. Clin Trials 5:93-106, 2008 (Pubitemid 351682519)
10. Van Hoe L, Van Cutsem E, Vergote I, et al: Size quantification of liver metastases in patients undergoing cancer treatment: Reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology 202:671-675, 1997 (Pubitemid 27093435)
11. Zhao B, James LP, Moskowitz CS, et al: Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252:263-272, 2009
12. Pappo AS, Patel SR, Crowley J, et al: R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for Research Through Collaboration study. J Clin Oncol 29:4541-4547, 2011
13. Juergens H, Daw NC, Geoerger B, et al: Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534-4540, 2011
14. Kurzrock R, Patnaik A, Aisner J, et al: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16:2458-2465, 2010
15. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP- 751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11:129-135, 2010
16. Stephens PJ, Greenman CD, Fu B, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40, 2011
17. Hancock JD, Lessnick SL: A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7:250-256, 2008 (Pubitemid 351366526)
18. Finkeltov I, Kuhn S, Glaser T, et al: Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 21:1890-1898, 2002 (Pubitemid 34259192)
19. Karnieli E, Werner H, Rauscher FJ 3rd, et al: The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 271:19304-19309, 1996 (Pubitemid 26271599)
20. Pappo AS, Patel S, Crowley J, et al: Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. J Clin Oncol 28:698s, 2010 (abstr 10000)
21. Gualberto A, Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 28:3009-3021, 2009